Agile Therapeutics shares took a dip on Tuesday after the company announced a key FDA approval for its new weekly contraceptive patch. Yet, one analyst sees great long-term potential, targeting the...
Here are five health-care-related stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross.
While more suited for aggressive accounts, these five stocks could prove exciting additions to portfolios looking for solid alpha potential.
The top analyst upgrades, downgrades and initiations seen on Friday included American Tower, Applied Materials, Exelon, Hubspot, Schlumberger, Shopify, Splunk and Zendesk.
The top analyst upgrades, downgrades and other research calls from Thursday include Arch Coal, Editas Medicine, FireEye, Generac, NextEra Energy and Under Armour.
The top analyst upgrades, downgrades and other research calls from Thursday include Chipotle Mexican Grill, Dick's Sporting Goods, Gentex, HP, Lowe's and Teva Pharmaceutical.
Although Agile Therapeutics stock is down year to date, it’s actually more or less doubled since January. So now might be the time to take some profit.
Stocks were indicated to open only slightly higher on Wednesday after a mixed bag of corporate earnings. What investors need to understand is that the major equity indexes remain just under all-time...
Although the tailwind of the Trump rally has been incredibly strong, there are still companies holding back this rally. In fact, the Dow was just barely short of hitting the 20,000 mark for the first...
January 4, 2017: Here are three stocks trading with relatively heavy volume among 17 equities making new 52-week lows in Wednesday’s session. On the NYSE, advancers led decliners by nearly 6 to...
A few biotech and pharma companies were on the move Wednesday, some making absolutely massive gains on the day, giving more credence to the Trump rally and positive sentiment for the health care...
Agile Therapeutics fell in Friday’s session, despite the broad markets taking off, after the company announced the pricing for its secondary offering.
These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current trading levels.
While there is absolutely no guarantee that any of these companies catch a bid and be bought out, they all have outstanding pipelines and prospects.
Thursday's top analyst upgrades, downgrades and initiations include Apple, Envestnet, Pandora Media, Regeneron Pharmaceuticals, Spectra Energy and Travelers.